Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast

Rosalba Torrisi, Silvia Zanardi, Floriana Pensa, Guglielmo Valenti, Vincenzina De Franchis, Guido Nicolo, Antonella Barreca, Francesco Minuto, Francesco Boccardo

Research output: Contribution to journalArticle

Abstract

The intracystic electrolyte content is generally used to identify different breast cyst subpopulations: cysts containing high K+ levels have been associated with an increased risk of subsequent breast cancer. In order to define whether other biochemical features of breast cyst fluid (BCF) might further explain such an increased risk, we determined the content of epidermal growth factor (EGF), a known mitogenic factor for normal and transformed breast epithelium, in cysts of women with breast cancer or proliferative lesions of the breast (atypical ductal or lobular hyperplasia and proliferative disease without atypia). Median intracystic EGF levels were significantly higher in patients with breast cancer or atypical hyperplasia than in cysts of women without any clinical or instrumental evidence of proliferative disease chosen as controls (p <0.05 and p <0.01, respectively). In patients affected by proliferative disease without atypia, intracystic EGF levels were not different either from controls or from the other study groups. No significant difference among groups was observed in the prevalence of Na+/K+<3 cysts, this being the most frequently observed type of cysts in all groups except in that with proliferative disease without atypia. No significant difference in EGF levels between cysts ipsilateral or contralateral to the biopsy was observed within each histological group. Our results indicate that EGF levels are higher in cysts aspirated from breasts with an associated proliferative pathology, either benign or neoplastic. The determination of intracystic EGF, combined with that of electrolyte content, might help to identify a subset of patients with gross cystic disease of the breast at potentially higher risk of developing breast cancer.

Original languageEnglish
Pages (from-to)219-224
Number of pages6
JournalBreast Cancer Research and Treatment
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 1995

Fingerprint

Breast Cyst
Cyst Fluid
Breast Diseases
Epidermal Growth Factor
Cysts
Breast Neoplasms
Electrolytes
Hyperplasia
Breast
Fibrocystic Breast Disease
Epithelium
Pathology
Biopsy

Keywords

  • benign breast disease
  • breast cyst fluid
  • EGF
  • gross cystic disease
  • proliferative breast disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast. / Torrisi, Rosalba; Zanardi, Silvia; Pensa, Floriana; Valenti, Guglielmo; De Franchis, Vincenzina; Nicolo, Guido; Barreca, Antonella; Minuto, Francesco; Boccardo, Francesco.

In: Breast Cancer Research and Treatment, Vol. 33, No. 3, 03.1995, p. 219-224.

Research output: Contribution to journalArticle

Torrisi, Rosalba ; Zanardi, Silvia ; Pensa, Floriana ; Valenti, Guglielmo ; De Franchis, Vincenzina ; Nicolo, Guido ; Barreca, Antonella ; Minuto, Francesco ; Boccardo, Francesco. / Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast. In: Breast Cancer Research and Treatment. 1995 ; Vol. 33, No. 3. pp. 219-224.
@article{ef3894b98b7c413381b29b159a8769be,
title = "Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast",
abstract = "The intracystic electrolyte content is generally used to identify different breast cyst subpopulations: cysts containing high K+ levels have been associated with an increased risk of subsequent breast cancer. In order to define whether other biochemical features of breast cyst fluid (BCF) might further explain such an increased risk, we determined the content of epidermal growth factor (EGF), a known mitogenic factor for normal and transformed breast epithelium, in cysts of women with breast cancer or proliferative lesions of the breast (atypical ductal or lobular hyperplasia and proliferative disease without atypia). Median intracystic EGF levels were significantly higher in patients with breast cancer or atypical hyperplasia than in cysts of women without any clinical or instrumental evidence of proliferative disease chosen as controls (p <0.05 and p <0.01, respectively). In patients affected by proliferative disease without atypia, intracystic EGF levels were not different either from controls or from the other study groups. No significant difference among groups was observed in the prevalence of Na+/K+<3 cysts, this being the most frequently observed type of cysts in all groups except in that with proliferative disease without atypia. No significant difference in EGF levels between cysts ipsilateral or contralateral to the biopsy was observed within each histological group. Our results indicate that EGF levels are higher in cysts aspirated from breasts with an associated proliferative pathology, either benign or neoplastic. The determination of intracystic EGF, combined with that of electrolyte content, might help to identify a subset of patients with gross cystic disease of the breast at potentially higher risk of developing breast cancer.",
keywords = "benign breast disease, breast cyst fluid, EGF, gross cystic disease, proliferative breast disease",
author = "Rosalba Torrisi and Silvia Zanardi and Floriana Pensa and Guglielmo Valenti and {De Franchis}, Vincenzina and Guido Nicolo and Antonella Barreca and Francesco Minuto and Francesco Boccardo",
year = "1995",
month = "3",
doi = "10.1007/BF00665946",
language = "English",
volume = "33",
pages = "219--224",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast

AU - Torrisi, Rosalba

AU - Zanardi, Silvia

AU - Pensa, Floriana

AU - Valenti, Guglielmo

AU - De Franchis, Vincenzina

AU - Nicolo, Guido

AU - Barreca, Antonella

AU - Minuto, Francesco

AU - Boccardo, Francesco

PY - 1995/3

Y1 - 1995/3

N2 - The intracystic electrolyte content is generally used to identify different breast cyst subpopulations: cysts containing high K+ levels have been associated with an increased risk of subsequent breast cancer. In order to define whether other biochemical features of breast cyst fluid (BCF) might further explain such an increased risk, we determined the content of epidermal growth factor (EGF), a known mitogenic factor for normal and transformed breast epithelium, in cysts of women with breast cancer or proliferative lesions of the breast (atypical ductal or lobular hyperplasia and proliferative disease without atypia). Median intracystic EGF levels were significantly higher in patients with breast cancer or atypical hyperplasia than in cysts of women without any clinical or instrumental evidence of proliferative disease chosen as controls (p <0.05 and p <0.01, respectively). In patients affected by proliferative disease without atypia, intracystic EGF levels were not different either from controls or from the other study groups. No significant difference among groups was observed in the prevalence of Na+/K+<3 cysts, this being the most frequently observed type of cysts in all groups except in that with proliferative disease without atypia. No significant difference in EGF levels between cysts ipsilateral or contralateral to the biopsy was observed within each histological group. Our results indicate that EGF levels are higher in cysts aspirated from breasts with an associated proliferative pathology, either benign or neoplastic. The determination of intracystic EGF, combined with that of electrolyte content, might help to identify a subset of patients with gross cystic disease of the breast at potentially higher risk of developing breast cancer.

AB - The intracystic electrolyte content is generally used to identify different breast cyst subpopulations: cysts containing high K+ levels have been associated with an increased risk of subsequent breast cancer. In order to define whether other biochemical features of breast cyst fluid (BCF) might further explain such an increased risk, we determined the content of epidermal growth factor (EGF), a known mitogenic factor for normal and transformed breast epithelium, in cysts of women with breast cancer or proliferative lesions of the breast (atypical ductal or lobular hyperplasia and proliferative disease without atypia). Median intracystic EGF levels were significantly higher in patients with breast cancer or atypical hyperplasia than in cysts of women without any clinical or instrumental evidence of proliferative disease chosen as controls (p <0.05 and p <0.01, respectively). In patients affected by proliferative disease without atypia, intracystic EGF levels were not different either from controls or from the other study groups. No significant difference among groups was observed in the prevalence of Na+/K+<3 cysts, this being the most frequently observed type of cysts in all groups except in that with proliferative disease without atypia. No significant difference in EGF levels between cysts ipsilateral or contralateral to the biopsy was observed within each histological group. Our results indicate that EGF levels are higher in cysts aspirated from breasts with an associated proliferative pathology, either benign or neoplastic. The determination of intracystic EGF, combined with that of electrolyte content, might help to identify a subset of patients with gross cystic disease of the breast at potentially higher risk of developing breast cancer.

KW - benign breast disease

KW - breast cyst fluid

KW - EGF

KW - gross cystic disease

KW - proliferative breast disease

UR - http://www.scopus.com/inward/record.url?scp=0028909470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028909470&partnerID=8YFLogxK

U2 - 10.1007/BF00665946

DO - 10.1007/BF00665946

M3 - Article

C2 - 7749149

AN - SCOPUS:0028909470

VL - 33

SP - 219

EP - 224

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -